In the morning of December 29, 2021, Deputy District Mayor Wang Nai of Huangpu District and his delegation visited the Shanghai branch of Sumitomo Pharma (Suzhou) Co., Ltd. (hereinafter referred to as "Sumitomo Pharma (Suzhou) Co., Ltd.") in Huangpu District to conduct an inspection of the corporate operation and provide guidance. The accompanying communication inspectors were Wang Jing, Director of the Dapuqiao Subdistrict Office, Dong Xiaohui, Deputy Chairwoman of the District Commerce Commission, Lou Wei, Deputy Director of the District Market Regulation Administration, Gu Chenxiao, Deputy Director of the District Financial Services Office, and Xu Weipeng, an official of the District Science and Technology Commission.  Sumitomo Pharma (Suzhou) Co., Ltd.CEO Naoki Noguchi, Senior Vice President Hiroki Uemukai, Senior Vice President Yasuhiro Kami, Senior Vice President Katsuyuki Kaitonaka, CLO Liu Ting, and other managements expressed a warm welcome on behalf of all employees.

At the beginning of the visit, Sumitomo Pharma (Suzhou) Co., Ltd. CEO Naoki Noguchi introduced and reported the company's operation to Deputy District Mayor Wang Nai and his delegation on behalf of the company, including Sumitomo Pharma (Suzhou) Co., Ltd.'s nearly 30 years of development in the Chinese market, its in-depth development in three major health fields of central nervous system disorders, infection prevention and cardiovascular diseases, its active introduction and provision of international innovative technology drugs for Chinese patients, as well as its active support and investment in environmental protection, mental health education, care for families and children of patients with mental disorders, education assistance, care for young and middle-aged individuals with hypertension, and emergency disaster relief in response to epidemics and floods.

Deputy District Mayor Wang Nai listened carefully to the company's presentation, affirming Sumitomo Pharma (Suzhou) Co., Ltd. original intention of being based in China and committed to providing better health solutions for Chinese patients. On behalf of the Huangpu District Government, he expressed the great concern of the government leadership team to Sumitomo Pharma (Suzhou) Co., Ltd. and encouraged the company to make further efforts and innovation to become a benchmark for foreign-invested pharmaceutical innovation enterprises in Huangpu District.

Deputy District Wang Nai also said that Huangpu District encourages the expectations of quality foreign-funded enterprises like  Sumitomo Pharma (Suzhou) Co., Ltd.to grow bigger and stronger, and would in turn create a more favorable trade environment, a more refined talent service environment, and a more foreign-friendly business environment for foreign-funded enterprises. During the exchange, the Subdistrict Office, the District Commerce Commission, the District Market Supervision Administration, the District Financial Office, and the District Science and Technology Commission provided practical guidance for the future development of Sumitomo Pharma (Suzhou) Co., Ltd. from the perspective of each functional department and offered many suggestions about industrial resources and government support projects.

Sumitomo Pharma (Suzhou) Co., Ltd. CEO Naoki Noguchi expressed his gratitude to the leaders of the Huangpu District Government for their care for the company, especially the roles of the District Commerce Commission and other government departments in bridging the gap between foreign investors and enterprises and the Huangpu District Government in the field of foreign investment. Sumitomo Pharma (Suzhou) Co., Ltd. will proactively forge ahead and continue to contribute to the advancement of China's pharmaceutical and health industry.

About Sumitomo Pharma (Suzhou) Co., Ltd.:

Since its establishment in China in the 1990s, Sumitomo Pharma (Suzhou) Co., Ltd. has developed China as one of its key market operating bases. The company has introduced advanced international manufacturing technologies to China and has provided high-quality products and pharmaceutical solutions in the fields of central nervous system disorders,  infection prevention, cardiovascular diseases and digestive diseases, benefiting numerous patients over the years. At the same time, the company also actively participates in various social welfare projects and fully supports the further development of health care in China. Sumitomo Pharma (Suzhou) Co., Ltd. adheres to its corporate mission of "Based in China, we will continue to create and contribute new value to human health and happiness", and will continue to provide high-quality pharmaceutical products with a "patient-oriented" mission to contribute to the long-term development of China's medical industry.